Effect of Iberogast (STW5) on tolerance to colonic gas in patients with irritable bowel syndrome : A randomized, double-blind, placebo control clinical trial
Aguilar, Ariadna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Benslaiman, Bouchra (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Serra Pueyo, Jordi (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)

Data:	2024
Resum:	Background: STW5 is an herbal medicinal product that, in previous studies, reduced abdominal pain in irritable bowel syndrome (IBS). The effect of STW5 on gas-related abdominal symptoms is unknown. Aim: To determine the effects of STW5, compared to placebo, on the responses to colonic gas in IBS. Methods: Using a cross-over design, two gas challenge tests were performed in 10 patients with IBS and bloating after 2-weeks treatment with (a) STW5 and (b) placebo. The challenge test consisted in continuous infusion of gas into the colon (24 mL/min for 60 min), followed by a 30-min free evacuation period. Gas evacuation, symptom perception, and abdominal distension were continuously registered. Results: Colonic gas filling was associated to a significant rise in abdominal symptom perception, that was significantly greater when patients were on-placebo (score increment 4. 0 ± 0. 3) compared with on-STW5 (score increment 3. 2 ± 0. 4; p = 0. 035). Gas filling was associated to a progressive abdominal distension that was similar with both treatments. Opening of the rectal cannula produced a massive gas evacuation, similar after both treatments, associated to a return of abdominal perception and distension to basal levels when patients were on-STW5 (score increment -0. 1 ± 0. 4; distension 0. 3 ± 0. 2 cm; p = 0. 399, and p = 0. 112 vs. basal), whereas both remained increased on-placebo (score increment 0. 5 ± 0. 3; distension 0. 8 ± 0. 3 cm; p = 0. 048, and p = 0. 016 vs. infusion start). Conclusions: STW5 improves colonic gas tolerance in IBS patients with bloating without a significant effect on gas retention and evacuation. This medicinal product can be beneficious for treatment of gas-related abdominal symptoms in patients with bloating. EudraCT: 2019-003976-38.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Abdominal distension ; Bloating ; Colonic gas ; Irritable bowel syndrome ; STW-5
Publicat a:	Neurogastroenterology & motility, 2024 , ISSN 1365-2982

DOI: 10.1111/nmo.14765

8 p, 867.3 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats